AWM
CRSP icon

Aevitas Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Aevitas Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,387
Closed -$491K – 127
2021
Q3 		$491K Buy
4,387
+100
+2% +$12.6K 0.31% 82
2021
Q2 		$694K Buy
4,287
+300
+8% +$36.5K 0.44% 62
2021
Q1 		$486K Buy
3,987
+240
+6% +$36.2K 0.34% 73
2020
Q4 		$574K Buy
+3,747
New +$443K 0.42% 61
2019
Q2 		– Sell
-2,317
Closed -$82K – 148
2019
Q1 		$82K Hold
2,317
– – 0.07% 148
2018
Q4 		$66K Sell
2,317
-1,500
-39% -$52.1K 0.07% 152
2018
Q3 		$169K Sell
3,817
-5,000
-57% -$262K 0.15% 111
2018
Q2 		$518K Buy
8,817
+1,971
+29% +$112K 0.5% 57
2018
Q1 		$313K Sell
6,846
-21,745
-76% -$897K 0.31% 78
2017
Q4 		$671K Buy
+28,591
New +$543K 0.64% 48

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Aevitas Wealth Management's CRSP Position: Q4 2021 in Review

Aevitas Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 4,387 shares — an estimated $491K sold.

Aevitas Wealth Management first reported a position in CRSP in Q4 2017 and held it in 10 quarters. The position peaked at $694K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Aevitas Wealth Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Aevitas Wealth Management sold 4,387 CRISPR Therapeutics shares in Q4 2021, an estimated $491K.
  • Aevitas Wealth Management first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 10 quarters.
  • Aevitas Wealth Management's CRISPR Therapeutics position peaked at $694K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Aevitas Wealth Management's 13F filing for Q4 2021, filed 19 Jan 2022.